Research Article| Volume 121, P76-87, June 2017

Effect of DHA supplementation on oxylipin levels in plasma and immune cell stimulated blood


      • Examination of acute and long-term effect of DHA on free oxylipin levels in plasma.
      • Up to 600% increase of DHA-oxylipins (HDHAs, EpDPEs, DiHDPEs).
      • Changes in the entire oxylipin profile suggest a cross-linked PUFA metabolism.
      • Slight increase in several EPA-derived hydroxy-FAs and dihydroxy-FAs.
      • Trend to a slight decline in arachidonic acid-derived oxylipin levels.



      EPA and DHA cause different physiological effects, which are in many cases mediated via their oxidative metabolites (oxylipins). However, metabolism studies investigating the effect of either EPA or DHA on comprehensive oxylipin patterns are lacking.

      Material and methods

      The short and long term (1, 3, 6, and 12 week) effect of 1076 mg/d DHA (free of EPA) on free (unesterified) oxylipin concentrations in plasma and lipopolysacharid (LPS) stimulated blood of 12 healthy men (mean age 25.1 ± 1.5 years) was investigated.


      After DHA supplementation, plasma levels of all DHA-oxylipins (HDHAs, EpDPEs, DiHDPEs) significantly increased (up to 600%) in a time-dependent fashion. Oxylipins of EPA and arachidonic acid (AA) were also affected. Whereas a slight increase in several EPA-derived hydroxy-FAs (including the RvE1 precursor 18-HEPE) and dihydroxy-FAs was observed after DHA supplementation, a trend to a slight decline in AA-derived oxylipin levels was found. In LPS stimulated blood, it is shown that DHA supplementation significantly reduces the ability of immune cells to form AA-derived COX (TXB2 and PGB2) and 12-LOX (12-HETE) eicosanoids. While no increase in EPA COX metabolites was found, n-3 PUFA 12-LOX metabolites of EPA (12-HEPE) and DHA (14-HDHA) were highly induced.


      We demonstrated that DHA supplementation causes a time-dependent shift in the entire oxylipin profile suggesting a cross-linked metabolism of PUFAs and subsequent formation of oxygenated lipid mediators.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Schunck W.-H.
        EPA and/or DHA? A test question on the principles and opportunities in utilizing the therapeutic potential of omega-3 fatty acids.
        J. Lipid Res. 2016; 57: 1608-1611
        • Allaire J.
        • Couture P.
        • Leclerc M.
        • Charest A.
        • Marin J.
        • Lépine M.-C.
        • Talbot D.
        • Tchernof A.
        • Lamarche B.
        A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study.
        Am. J. Clin. Nutr. 2016; 104: 280-287
        • Burdge G.C.
        • Calder P.C.
        Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults.
        Reprod. Nutr. Dev. 2005; 45: 581-597
        • Whelan J.
        The health implications of changing linoleic acid intakes.
        Prostaglandins Leukot. Essent. Fat. Acids. 2008; 79: 165-167
        • Tosi F.
        • Sartori F.
        • Guarini P.
        • Olivieri O.
        • Martinelli N.
        Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease.
        Adv. Exp. Med. Biol. 2014; 824: 61-81
        • Brenna J.T.
        • Salem N.
        • Sinclair A.J.
        • Cunnane S.C.
        International society for the study of fatty acids and lipids, ISSFAL, alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans.
        Prostaglandins Leukot. Essent. Fat. Acids. 2009; 80: 85-91
        • Plourde M.
        • Cunnane S.C.
        Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements.
        Appl. Physiol. Nutr. Metab. Physiol. Appl. Nutr. Metab. 2007; 32: 619-634
        • Grønn M.
        • Christensen E.
        • Hagve T.A.
        • Christophersen B.O.
        Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells.
        Biochim. Biophys. Acta. 1991; 1081: 85-91
        • Conquer J.A.
        • Holub B.J.
        Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects.
        J. Nutr. 1996; 126: 3032-3039
        • Grimsgaard S.
        • Bonaa K.H.
        • Hansen J.B.
        • Nordøy A.
        Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids.
        Am. J. Clin. Nutr. 1997; 66: 649-659
        • Mori T.A.
        • Burke V.
        • Puddey I.B.
        • Watts G.F.
        • O’Neal D.N.
        • Best J.D.
        • Beilin L.J.
        Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.
        Am. J. Clin. Nutr. 2000; 71: 1085-1094
        • Mori T.A.
        • Woodman R.J.
        • Burke V.
        • Puddey I.B.
        • Croft K.D.
        • Beilin L.J.
        Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects.
        Free Radic. Biol. Med. 2003; 35: 772-781
        • Balgoma D.
        • Checa A.
        • Sar D.G.
        • Snowden S.
        • Wheelock C.E.
        Quantitative metabolic profiling of lipid mediators.
        Mol. Nutr. Food Res. 2013; 57: 1359-1377
        • Gabbs M.
        • Leng S.
        • Devassy J.G.
        • Monirujjaman M.
        • Aukema H.M.
        Advances in our understanding of oxylipins derived from dietary PUFAs.
        Adv. Nutr. 2015; 6: 513-540
        • Arnold C.
        • Markovic M.
        • Blossey K.
        • Wallukat G.
        • Fischer R.
        • Dechend R.
        • Konkel A.
        • von Schacky C.
        • Luft F.C.
        • Muller D.N.
        • Rothe M.
        • Schunck W.-H.
        Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}–3 fatty acids.
        J. Biol. Chem. 2010; 285: 32720-32733
        • Morisseau C.
        • Hammock B.D.
        Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.
        Annu. Rev. Pharmacol. Toxicol. 2013; 53: 37-58
        • Serhan C.N.
        • Chiang N.
        • Dalli J.
        The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution.
        Semin. Immunol. 2015; 27: 200-215
        • Westphal C.
        • Konkel A.
        • Schunck W.-H.
        CYP-eicosanoids – a new link between omega-3 fatty acids and cardiac disease?.
        Prostaglandins Other Lipid Mediat. 2011; 96: 99-108
        • Agbor L.N.
        • Walsh M.T.
        • Boberg J.R.
        • Walker M.K.
        Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids.
        Toxicol. Appl. Pharmacol. 2012; 264: 351-360
        • Jung F.
        • Schulz C.
        • Blaschke F.
        • Muller D.N.
        • Mrowietz C.
        • Franke R.P.
        • Lendlein A.
        • Schunck W.-H.
        Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation.
        Clin. Hemorheol. Microcirc. 2012; 52: 403-416
        • Zhang G.
        • Panigrahy D.
        • Mahakian L.M.
        • Yang J.
        • Liu J.-Y.
        • Stephen Lee K.S.
        • Wettersten H.I.
        • Ulu A.
        • Hu X.
        • Tam S.
        • Hwang S.H.
        • Ingham E.S.
        • Kieran M.W.
        • Weiss R.H.
        • Ferrara K.W.
        • Hammock B.D.
        Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
        Proc. Natl. Acad. Sci. USA. 2013; 110: 6530-6535
        • Fischer R.
        • Konkel A.
        • Mehling H.
        • Blossey K.
        • Gapelyuk A.
        • Wessel N.
        • von Schacky C.
        • Dechend R.
        • Muller D.N.
        • Rothe M.
        • Luft F.C.
        • Weylandt K.
        • Schunck W.-H.
        Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway.
        J. Lipid Res. 2014; 55: 1150-1164
        • Shearer G.C.
        • Harris W.S.
        • Pedersen T.L.
        • Newman J.W.
        Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters.
        J. Lipid Res. 2010; 51: 2074-2081
        • Keenan A.H.
        • Pedersen T.L.
        • Fillaus K.
        • Larson M.K.
        • Shearer G.C.
        • Newman J.W.
        Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers.
        J. Lipid Res. 2012; 53: 1662-1669
        • Grapov D.
        • Adams S.H.
        • Pedersen T.L.
        • Garvey W.T.
        • Newman J.W.
        Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids.
        PLoS One. 2012; 7: e48852
        • Lundström S.L.
        • Yang J.
        • Brannan J.D.
        • Haeggström J.Z.
        • Hammock B.D.
        • Nair P.
        • O’Byrne P.
        • Dahlén S.-E.
        • Wheelock C.E.
        Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids.
        Mol. Nutr. Food Res. 2013; 57: 1378-1389
        • Nording M.L.
        • Yang J.
        • Georgi K.
        • Hegedus Karbowski C.
        • German J.B.
        • Weiss R.H.
        • Hogg R.J.
        • Trygg J.
        • Hammock B.D.
        • Zivkovic A.M.
        Individual variation in lipidomic profiles of healthy subjects in response to omega-3 fatty acids.
        PLoS One. 2013; 8: e76575
        • Schuchardt J.P.
        • Schmidt S.
        • Kressel G.
        • Dong H.
        • Willenberg I.
        • Hammock B.D.
        • Hahn A.
        • Schebb N.H.
        Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men.
        Prostaglandins Leukot. Essent. Fat. Acids. 2013; 89: 19-29
        • Schuchardt J.P.
        • Schmidt S.
        • Kressel G.
        • Willenberg I.
        • Hammock B.D.
        • Hahn A.
        • Schebb N.H.
        Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men.
        Prostaglandins Leukot. Essent. Fat. Acids. 2014; 90: 27-37
        • Schebb N.H.
        • Ostermann A.I.
        • Yang J.
        • Hammock B.D.
        • Hahn A.
        • Schuchardt J.P.
        Comparison of the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and esterified oxylipins.
        Prostaglandins Other Lipid Mediat. 2014; 113–115: 21-29
        • Newman J.W.
        • Pedersen T.L.
        • Brandenburg V.R.
        • Harris W.S.
        • Shearer G.C.
        Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects.
        PLoS One. 2014; 9: e111471
        • Shaik J.S.
        • Ahmad M.
        • Li W.
        • Rose M.E.
        • Foley L.M.
        • Hitchens T.K.
        • Graham S.H.
        • Hwang S.H.
        • Hammock B.D.
        • Poloyac S.M.
        Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.
        Am. J. Physiol. Heart Circ. Physiol. 2013; 305: H1605-H1613
        • Shearer G.C.
        • Newman J.W.
        Lipoprotein lipase releases esterified oxylipins from very low density lipoproteins.
        Prostaglandins Leukot. Essent. Fat. Acids. 2008; 79: 215-222
        • Schuchardt J.P.
        • Ostermann A.I.
        • Stork L.
        • Kutzner L.
        • Kohrs H.
        • Greupner T.
        • Hahn A.
        • Schebb N.H.
        Effects of docosahexaenoic acid supplementation on PUFA levels in red blood cells and plasma.
        Prostaglandins Leukot. Essent. Fat. Acids. 2016; 115: 12-23
        • Patrignani P.
        • Panara M.R.
        • Greco A.
        • Fusco O.
        • Natoli C.
        • Iacobelli S.
        • Cipollone F.
        • Ganci A.
        • Créminon C.
        • Maclouf J.
        Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.
        J. Pharmacol. Exp. Ther. 1994; 271: 1705-1712
        • Kutzner L.
        • Ostermann A.I.
        • Konrad T.
        • Riegel D.
        • Hellhake S.
        • Schuchardt J.P.
        • Schebb N.H.
        Lipid class specific quantitative analysis of n-3 polyunsaturated fatty acids in food supplements.
        J. Agric. Food Chem. 2017; 65: 139-147
        • Plourde M.
        • Chouinard-Watkins R.
        • Vandal M.
        • Zhang Y.
        • Lawrence P.
        • Brenna J.T.
        • Cunnane S.C.
        Plasma incorporation, apparent retroconversion and β-oxidation of 13C-docosahexaenoic acid in the elderly.
        Nutr. Metab. 2011; 8: 5
        • Stark K.D.
        • Holub B.J.
        Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy.
        Am. J. Clin. Nutr. 2004; 79: 765-773
        • Giltay E.J.
        • Gooren L.J.
        • Toorians A.W.
        • Katan M.B.
        • Zock P.L.
        Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects.
        Am. J. Clin. Nutr. 2004; 80: 1167-1174
        • Metherel A.H.
        • Armstrong J.M.
        • Patterson A.C.
        • Stark K.D.
        Assessment of blood measures of n-3 polyunsaturated fatty acids with acute fish oil supplementation and washout in men and women.
        Prostaglandins Leukot. Essent. Fat. Acids. 2009; 81: 23-29
        • Ostermann A.I.
        • Willenberg I.
        • Schebb N.H.
        Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS.
        Anal. Bioanal. Chem. 2015; 407: 1403-1414
        • Willenberg I.
        • Rund K.
        • Rong S.
        • Shushakova N.
        • Gueler F.
        • Schebb N.H.
        Characterization of changes in plasma and tissue oxylipin levels in LPS and CLP induced murine sepsis.
        Inflamm. Res. Off. J. Eur. Histamine Res. Soc. 2016; 65: 133-142
        • Ostermann A.I.
        • Schebb N.H.
        Effects of omega-3 fatty acid supplementation on the pattern of oxylipins – a short review about the modulation of hydroxy-, dihydroxy-, and epoxy-fatty acids.
        Food Funct. 2017;
        • Caligiuri S.P.
        • Aukema H.M.
        • Ravandi A.
        • Pierce G.N.
        Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption.
        Exp. Gerontol. 2014; 59: 51-57
        • Willenberg I.
        • Ostermann A.I.
        • Schebb N.H.
        Targeted metabolomics of the arachidonic acid cascade: current state and challenges of LC-MS analysis of oxylipins.
        Anal. Bioanal. Chem. 2015; 407: 2675-2683
        • McManus S.
        • Tejera N.
        • Awwad K.
        • Vauzour D.
        • Rigby N.
        • Fleming I.
        • Cassidy A.
        • Minihane A.M.
        Differential effects of EPA versus DHA on postprandial vascular function and the plasma oxylipin profile in men.
        J. Lipid Res. 2016; 57: 1720-1727
        • Oh S.F.
        • Pillai P.S.
        • Recchiuti A.
        • Yang R.
        • Serhan C.N.
        Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.
        J. Clin. Investig. 2011; 121: 569-581
        • Salic K.
        • Morrison M.C.
        • Verschuren L.
        • Wielinga P.Y.
        • Wu L.
        • Kleemann R.
        • Gjorstrup P.
        • Kooistra T.
        Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
        Atherosclerosis. 2016; 250: 158-165
        • Schuchardt J.P.
        • Schneider I.
        • Willenberg I.
        • Yang J.
        • Hammock B.D.
        • Hahn A.
        • Schebb N.H.
        Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA.
        Prostaglandins Other Lipid Mediat. 2014; 109–111: 23-31
        • Demasi M.
        • Caughey G.E.
        • James M.J.
        • Cleland L.G.
        Assay of cyclooxygenase-1 and 2 in human monocytes.
        Inflamm. Res. Off. J. Eur. Histamine Res. Soc. 2000; 49: 737-743
        • Wall R.
        • Ross R.P.
        • Fitzgerald G.F.
        • Stanton C.
        Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids.
        Nutr. Rev. 2010; 68: 280-289
        • Gomolka B.
        • Siegert E.
        • Blossey K.
        • Schunck W.-H.
        • Rothe M.
        • Weylandt K.H.
        Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples.
        Prostaglandins Other Lipid Mediat. 2011; 94: 81-87